Parkinson's disease (PD) is a multisystem alpha-synucleinopathic neurodegenerative
disease and the most prevalent neurodegenerative disorder after Alzheimer's disease with a …

There are currently no effective biomarkers for diagnosing Parkinson's disease (PD) or
tracking its progression. Here, we developed an artificial intelligence (AI) model to detect PD …

Neuropsychiatric mood and motivation symptoms (depression, anxiety, apathy, impulse
control disorders) in Parkinson's disease (PD) are highly disabling, difficult to treat and …

Parkinson's disease (PD) is associated with excessive beta activity in the basal ganglia.
Brain sensing implants aim to leverage this biomarker for demand-dependent adaptive …

Background Sleep dysfunction is disabling in people with Parkinson's disease and is linked
to worse motor and non-motor outcomes. Sleep-specific adaptive Deep Brain Stimulation …

Beta-band activity in the subthalamic local field potential (LFP) is correlated with Parkinson's
disease (PD) symptom severity and is the therapeutic target of deep brain stimulation (DBS) …

Sleep disturbance is a prevalent and disabling comorbidity in Parkinson's disease (PD). We
performed multi-night (n= 57) at-home intracranial recordings from electrocorticography and …

Adaptive deep brain stimulation (aDBS) is a promising new technology with increasing use
in experimental trials to treat a diverse array of indications such as movement disorders …

Background Sleep disturbances are highly prevalent in movement disorders, potentially due
to the malfunctioning of basal ganglia structures. Pallidal deep brain stimulation (DBS) has …

Rapid eye movement (REM) sleep behavior disorder (RBD) is associated with Parkinson's
disease (PD). In this study, a smartwatch-based sensor is utilized as a convenient tool to …